SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Definitive is an onchain trading platform democratizing advanced trading tools for the masses. Trade any token on any chain with advanced trade order types including Market, Limit Buy/Sell, Stop Loss and TWAP orders.  Route your trade instantly across 100+ DEXs and liquidity pools to get the best prices on every trade. Definitive is built by former Coinbase Institutional trading alumni and active DeFi experts.

Definitive

EDGE is trending as it demonstrates remarkable resilience and outperformance, staying green amidst broader crypto market weakness, which the community believes signals its potential for a significant 'altcoin season' rally, further fueled by recent token buybacks and upcoming platform developments.

Permian Resources Holdings, Inc. engages in the exploration and production of oil and natural gas. It also focuses on driving sustainable returns through the responsible acquisition, optimization, and development of crude oil. The company was founded on October 6, 2014 and is headquartered in Midland, TX.

Permian Resources Holdings Inc. - Ordinary Shares - Class A

Permian Resources Corp - Ordinary Shares - Class A

Permian Resources is trending as multiple analyst upgrades and raised price targets fuel community optimism, highlighting its strong financial performance, strategic acquisitions, and status as a leading Permian Basin operator, with many speculating about its potential as a buyout candidate.

Index Coop is a decentralized autonomous organization (DAO) that builds structured DeFi products and strategy tokens. Index Coop offers a suite of sector index products, leverage and inverse products, and yield-generating products. The product suite runs on Set Protocol, an audited, self-custodial DeFi tool that allows for the creation and management of Ethereum-based (or ERC-20) tokens. Changes to the DAO are voted on by the owners of a governance token called INDEX and then implemented by a team of developers. INDEX holders wield voting power on a 1:1 basis, meaning one token equals one vote.

Index Cooperative

Index Cooperative is trending due to recent product innovations, including Smart Loops for automated leveraged staking and new leveraged tokens, alongside a recent exchange listing that has piqued community interest. Traders are actively discussing its potential for explosive growth, citing its low circulating supply and micro-cap status, with many accumulating in anticipation of a significant price movement.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending following a $75 million direct offering to a new institutional investor, igniting intense community debate over whether this strategic funding validates its "best-in-class" MASH drug for a potential partnership, or if it represents desperate dilution.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk ($TTD) is trending as investors grapple with an abrupt CFO departure and rescheduled earnings, sparking intense community debate. Many are questioning CEO Jeff Green's management and stock-based compensation, pushing the stock lower amidst broader pressure on the software sector.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin ($BNKR) is trending due to its strong performance on the Base chain and its connection to the booming AI agent narrative, with the community actively discussing its utility in AI-powered trading, growing holder base, and potential to shed zeros as it pushes towards new price levels amidst overall crypto market volatility.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is generating significant buzz due to technical indicators suggesting a potential bullish reversal, with community members highlighting strengthening demand and recent large-scale whale accumulation. The token is also gaining attention for a rapid increase in new addresses on Shibarium, though opinions remain polarized between optimists anticipating a breakout and long-term holders expressing frustration over its trajectory.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

A deeply divided community is actively debating Algorand's future, spurred by recent changes to its Foundation's leadership, including new board appointments and a controversial shift to a for-profit entity raising concerns about transparency and token supply. This, alongside a significant pump in its ecosystem token $FOLKS, intensifies speculation on ALGO's long-term viability and potential for a rebound in the volatile altcoin market.

ProShares Trust - ProShares Ultra Silver 2x Shares

ProShares Ultra Silver

ProShares Ultra Silver (AGQ) is trending amid extreme volatility, experiencing a dramatic rise and subsequent sharp decline that has the community intensely discussing the inherent risks of leveraged ETFs, including volatility decay and potential liquidation. Many are debating whether silver's recent price action is a speculative "pump and dump" detached from fundamentals, creating significant division between bullish hopefuls and those predicting further market correction.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Anticipation is high for Super Micro Computer's upcoming Q2 earnings, with investors debating potential massive revenue growth driven by surging AI demand against persistent concerns over razor-thin margins. The community is highly polarized, with calls for a short squeeze contrasting fears of continued management and execution challenges.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums

ELV tops Q4 EPS estimates as premiums grow and Carelon revenues surge, even as medical membership slips and expenses climb.

Centene Expands Palliative Care Access in Ohio Through Tuesday Health

CNC teams up with Tuesday Health to expand palliative care in Ohio, blending in-person and virtual support.

Zacks Research Upgrades Fortress Biotech (NASDAQ:FBIO) to Strong-Buy

Zacks Research upgraded shares of Fortress Biotech from a "hold" rating to a "strong-buy" rating in a research report on Wednesday...

Research Analysts Set Expectations for FBIO FY2025 Earnings

Fortress Biotech, Inc. (NASDAQ:FBIO - Free Report) - Stock analysts at HC Wainwright issued their FY2025 earnings per share estimates for shares of Fortress Biotech in a research report issued to...

Morning Market Brief: From IP Land Grabs to FDA Greenlights, Small-Cap Innovation Takes Center Stage

<ul class="summary-bullets"><li>The FDA’s green light comes after Sentynl Therapeutics, fully owned by Zydus Lifesciences, assumed responsibility for developing and commercializing CUTX-101.</li><li>Cyprium stands to earn tiered royalties on ZYCUBO sales and up to $129 million in potential development and sales milestones from Sentynl.</li><li>Children receiving early treatment with ZYCUBO had a nearly 80% lower risk of death compared with untreated patients.&nbsp;</li></ul>Fortress Biotech, Inc. (FBIO) and its majority-owned unit, Cyprium Therapeutics, announced on Tuesday that the U.S. Food and Drug Administration (FDA) has officially approved ZYCUBO (formerly CUTX-101) for treating Menkes disease in children.The FDA’s green light comes after Sentynl Therapeutics, fully owned by Zydus Lifesciences, assumed responsibility for developing and commercializing CUTX-101 from Cyprium in December 2023.<blockquote>“The approval of ZYCUBO is a pivotal milestone for our company and patients suffering from Menkes Disease, as it is the first and only FDA-approved treatment for this rare, often fatal, pediatric disease.”-Lindsay A. Rosenwald, Chairman, President and CEO, Fortress Biotech</blockquote><h2 class="st-heading-2">Approval And Benefits</h2>The approval also includes a Rare Pediatric Disease Priority Review Voucher, which will be transferred to Cyprium. Additionally, Cyprium stands to earn tiered royalties on ZYCUBO sales and up to $129 million in potential development and sales milestones from Sentynl.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/FBIO">Fortress Biotech stock</a> traded over 12% higher in Tuesday’s premarket. On Stocktwits, retail sentiment around the stock improved to ‘extremely bullish’ from ‘bullish’ territory the previous day. Message volume changed to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_13_083353_png_10f3be8db7.webp" alt="FBIO’s Sentiment Meter and Message Volume as of 07:40 a.m. ET on Jan. 13, 2026 | Source: Stocktwits" width="927" height="102"><figcaption>FBIO’s Sentiment Meter and Message Volume as of 07:40 a.m. ET on Jan. 13, 2026 | Source: Stocktwits</figcaption></figure>Menkes disease is a rare genetic disorder caused by mutations in the ATP7A gene, which disrupt copper absorption and transport in infants. Without treatment, the disease can be fatal, as copper is essential for brain development.&nbsp;<h2 class="st-heading-2">ZYCUBO Efficiency&nbsp;</h2>ZYCUBO, administered as a subcutaneous injection, helps restore copper balance in the body and maintain adequate levels in patients with Menkes disease.Results supporting approval showed that children receiving early treatment with ZYCUBO had a nearly 80% lower risk of death compared with untreated patients. Median overall survival in the treated group was 177.1 months, compared with 17.6 months in the external control group.&nbsp;FBIO stock has gained over 113% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/delta-airlines-stock-falls-2026-guidance-boeing-order/cmUXI2vR44s">Delta Air Lines Stock Tumbles Despite Q4 Earnings Beat – Even A Boeing Order Failed To Lift Confidence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Fortress Biotech logo is displayed on the screen of a tablet.

FBIO Stock Surges 12% Pre-Market After It Wins FDA Approval For Rare Pediatric Menkes Disease

FDA’s ZYCUBO approval also includes a Rare Pediatric Disease Priority Review Voucher, which will be transferred to Cyprium.

Equity

FDA’s ZYCUBO approval also includes a Rare Pediatric Disease Priority Review Voucher, which will be transferred to Cyprium.


Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above Two Hundred Day Moving Average - What's Next?

Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above 200 Day Moving Average - Should You Sell...

Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above 200-Day Moving Average - Here's What Happened

Fortress Biotech (NASDAQ:FBIO) Stock Price Crosses Above 200 Day Moving Average - Here's Why...

Envestnet Asset Management Inc. Sells 98,195 Shares of Fortress Biotech, Inc. $FBIO

Envestnet Asset Management Inc. lessened its holdings in Fortress Biotech, Inc. (NASDAQ:FBIO - Free Report) by 36.7% during the second quarter, according to its most recent 13F filing with the...

Fortress Biotech (NASDAQ:FBIO) Upgraded at Wall Street Zen

Wall Street Zen upgraded Fortress Biotech from a "hold" rating to a "buy" rating in a report on Sunday...

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Current Price	$3.10
Prev Close	$3.36
Open	$3.30
Dividend Yield	0.00%
50-Day Moving Average	$3.33
Beta	0.94
Avg. Volume	536,793.77
PE Ratio	-11.58

52-Week High	$4.53
52-Week Low	$1.33
Market Capitalization	$104.29M
EPS (Annual)	-$2.69
Price to Book	1.72
Revenue Per Employee	$571,039.60
Enterprise Value/EBITDA	N/A

FBIO
Fortress Biotech Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FBIO News

FBIOFortress Biotech Inc